The breakthrough research results of our country's treatment of heavy soil poverty

In recent days, a major breakthrough has been made in the clinical research of China's new gene editing technology, which is expected to completely eliminate the dilemma of "blood transfusion for life-saving" for patients with severe beta-thalassemia. On April 8th, the research team for the prevention and treatment of beta-thalassemia of the First Affiliated Hospital of Guangxi Medical University, in collaboration with ShanghaiTech University, Fudan University, and Anhui Bio-organism, published a groundbreaking achievement titled "Clinical Application of Base Editing Technology in the Treatment of Beta-Thalassemia" in the top international academic journal Nature. This study revealed the world's first clinical application results of base editing drugs for transfusion-dependent beta-thalassemia, marking the international recognition of the clinical transformation of China's original gene editing technology. It also signifies that this original Chinese gene technology will bring hope to thalassemia patients by freeing them from a lifetime of blood transfusions.